单克隆抗体DGDK-1导向治疗晚期肝癌临床研究  

Clinical Study of ^(131)Ⅰ-Hepama-1 Monoclonal Antibody in Targeting Therapy of Advanced Liver Cancer

作　　者：尚育红[1] 许莉[1] 牛广军[2] 范魁生[1] 谢弘[3] 王根风[3] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州市450052 [2]郑州大学第一附属医院核医学科,郑州市450052 [3]中国科学院上海生命科学院生物化学与细胞生物学研究所,上海市200031

出　　处：《医药论坛杂志》2004年第21期13-14,16,共3页Journal of Medical Forum

摘　　要：目的　观察13 1Ⅰ标记肝癌单克隆抗体Hepama治疗晚期肝癌的疗效。方法　采用13 1Ⅰ -Hepama - 1单克隆抗体周转静脉注射治疗 2 8例失去手术时机的晚期肝癌患者。结果　多数患者癌性症状减轻 ,生活质量提高 ,CR +PR +MR率为 4 6 4 % (13/ 2 8) ,1年生存率 2 1 4 % (6 / 2 8) ,且对人体肾功能及甲状腺功能无明显影响(P>0 .0 5 )。结论　13 1Ⅰ -Hepama- 1周围静脉注射治疗晚期肝癌 ,疗效肯定 ,方法简便安全 ,不良反应轻 ,可作为晚期肝癌治疗方法之一 。Objective To evaluate 131Ⅰ-Hepama-1 monoclonal antibody targeting therapy in advanced liver cancer. Methods 28 patients with advanced liver cancer were treated with 131Ⅰ-Hepama-1 monoclonal antibody injected into the peripheral veins.Results Improvement of symptoms and signs were observed in most of the treated patients in addition to improvement of quality of life.The over-all rate of CR+PR+MR was 46.4% (13/28),and the 1-year survival rate was 21.4%(6/28),and was no side effects for kidney and thyroid gland function test(P>0.05).Conclusion The targeting therapy with 131I-Hepama-1 monoclonal antibody provided high effectiveness,less side-effects and worth futher study.

关 键 词：单克隆抗体 DGDK-1 导向治疗 晚期肝癌 静脉注射 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]